Egypt reads your GMP certificate instead of visiting

Britain is on the list — and off the fastest track

EDA's reference-country list for medicines runs to twenty-four names, and it is built country by country with no European Union bloc entry at all. Ireland, Germany and France are each listed individually, and so is the United Kingdom, third on the list. Brexit is structurally irrelevant here: there was never a bloc entry for Britain to fall out of.

That list drives the reliance pathways. The verification route needs approval by at least two of those authorities, or one plus World Health Organization prequalification. The abridged route needs one. Both require the dossier to be the same one you filed with the reference agency, an unredacted assessment report, and a certificate of pharmaceutical product.

Four waivers, and the first one is the expensive one

• On-site inspection of your factory

  EDA's own words: imported medicinal products from reference countries are "waived from EDA on-site inspection as a prerequisite for approving the manufacturing site. Whereas EDA shall only review the site valid GMP certificate"

  Waived
• Bioequivalence and bioavailability studies

  A waiver is available for innovator products and for imported generics already approved by one of the reference authorities

  Available
• Active substance quality

  Recognised through WHO prequalification of the API, or a European certificate of suitability

  Recognised
• Stability data

  EDA will rely on stability data generated in the country of origin rather than requiring it regenerated for Zone IV conditions

  Relied on
• Track A and B fast lanes

  Defined by FDA and EMA approval. A UK authorisation is not named

  Not on the wording

From EDA's reliance practices guideline, version 4, issued and effective 11 August 2024. Sites outside the reference countries need a valid inspection accreditation report from a stringent authority or a certifying international body instead. Note that Egypt is not a member of the international inspection cooperation scheme — it applied for pre-accession in September 2023 — so this waiver is EDA's own policy rather than a consequence of mutual membership.

The longest authorisation on this site, and a four-year grace period

A human pharmaceutical marketing authorisation in Egypt runs ten years, against five in Saudi Arabia, five in the UAE and five for South African establishment licences. Re-registration is applied for during the last year of validity.

And if you miss it, the consequence is unusually forgiving: a product holding preliminary approval to proceed with re-registration is granted a grace period of up to four years from the expiry date. There is also a mid-term obligation that is easy to overlook — a safety, quality and efficacy report during the last three months of the fifth year.

From EDA's re-registration guideline, version 7, issued 30 December 2025 and effective 1 January 2026 — the clearest published clock we found for any Egyptian medicines process.

Five applicant types, and no obligation to manufacture locally

EDA's registration guideline permits applications from licensed local pharmaceutical factories, factories under construction, toll manufacturing companies, scientific offices and authorised import companies. For an imported product the file needs a valid and legalised agency agreement or authorisation letter between the licence holder and the applicant, plus a legalised certificate of pharmaceutical product.

A sourced negative worth having, because the opposite is widely assumed: there is no requirement to manufacture or toll-manufacture in Egypt. Toll manufacturing is an option with its own slot limits, not a condition of registration. What does exist is policy pressure rather than law — EDA's published strategy to 2030 targets localising the top fifty imported active ingredients, about seventy-eight per cent of API imports by value, and notes that local production already covers around ninety-one per cent of the market.

The part we cannot show you, and will not guess

Pricing runs as a separate process alongside registration, and approval must be obtained before registration completes. Products manufactured locally for export only, or for export and tender only, are exempt from pricing altogether. Those facts are from EDA's own guideline.

Beyond them, the published record thins sharply. The governing instrument is a ministerial decree of 2012, and neither its text nor its annexed list of reference countries is retrievable from any official Egyptian publication we could reach — the relevant EDA register pages refuse automated access. So the single question a UK company asks about Egyptian pricing, whether Britain is in the basket, we cannot answer. We are not going to answer it from a law firm's summary.

From an EDA pricing-mechanism document. Two timing rules come with them: a company may not apply for a price increase within one year of its previous pricing under the current criteria, while a decrease may be requested at any time and takes effect within three months of approval. Registration fees are published only as amounts embedded in the prose of one dossier guideline — EGP 1,000 to file a registration request, EGP 20,000 for a scientific office permission letter for imported products — and there is no published tariff by product type, no variation fee and no inspection fee amount.

Your own government logged this market as a barrier, and closed it

The Department for Business and Trade maintains a public register of trade barriers. Egypt carried one for pharmaceuticals: UK businesses faced "significant delays when registering pharmaceutical products". It was reported in November 2019.

It is now marked resolved, in March 2025 — with the resolution attributed to regulatory capacity-building between NICE, the MHRA, the Department of Health and Social Care and the Egyptian authorities, and registration timelines described as having moved from years down to months.

The UK–Egypt Association Agreement, signed in December 2020, covers goods, services, sanitary measures, intellectual property and government procurement. It contains no pharmaceutical or conformity-assessment provision. The regulatory relationship here runs through that capacity-building work, not through the trade agreement.

One buyer, and we could not read its rules

The same law that created EDA created a unified procurement authority for the public health sector. On law-firm authority it is the exclusive purchaser of pharmaceutical products and medical equipment for all governmental and public entities, takes a fee of up to seven per cent of procurement value, and public bodies may not buy directly except in Cabinet-approved emergencies. Supplier registration with it appears to be separate from EDA product registration.

We could not confirm any of that from the authority itself. Its website refused every request we made, on the root and on every subpage. So the mandate, the exclusivity, the fee and the supplier registration requirements are reported here as what they are: assertions by Egyptian counsel that we have not been able to verify against the source.

What is better established is the procurement preference: Egypt's public contracting law gives a price preference of fifteen per cent to bidders supplying products that meet a minimum local-content percentage. The article number we could not obtain.

Currency, from the Fund rather than the central bank

Egypt floated the pound in March 2024. The International Monetary Fund's March 2026 report records that there was no introduction or intensification of exchange restrictions or multiple currency practices inconsistent with Article VIII, and no capital flow management measures introduced in 2025, that the spread with parallel market measures remained closed with no foreign exchange backlogs, and that the central bank refrained from direct intervention through 2025. Reserves stood at 59.2 billion dollars at December 2025.

Two honest qualifications. The Fund's earlier report notes anecdotal evidence of some difficulty obtaining currency for current transactions even while market participants raised no significant issues. And every currency finding on this page comes from the Fund alone — the Central Bank of Egypt refuses automated access, so we have not read a single central bank circular directly. No priority foreign-exchange allocation for medicines appears anywhere in the accessible record.

Your own government's export guidance for Egypt advises secure payment terms, citing average dispute resolution of 1,010 days at around 26% of the claim value. That is a contract-drafting point rather than a currency one, and it is worth more attention than the exchange rate.

What we could not confirm

• Whether the UK is in the pricing basket

  The 2012 pricing decree and its annexed country list are not retrievable from any official Egyptian source we could reach. No source of any kind that we found names the basket members.

• The live review clocks

  The master timetable sits in an appendix to the registration guideline that did not render. The widely quoted thirty and sixty day figures belong to a withdrawn version.

• A consolidated fee tariff

  EDA publishes an Arabic service catalogue with the right rows — including foreign factory inspection priced by continent — and no visible amounts. Medicine fees appear only as figures embedded in guideline prose.

• The procurement authority's own rules

  Its website refused every request. Exclusivity, the seven per cent fee and supplier registration rest on Egyptian counsel, not on the source.

• The September 2026 pricing overhaul

  Announced by the chairman, reported in detail by the trade press, and traceable to no decree number or date as at the day we checked.

• The licensed bioequivalence centres

  Studies must be run at EDA-licensed centres. The list of them is not published, and neither are the rules for licensing one.

Three of the four Egyptian official domains this page needed refuse automated access. Everything stated as fact above was read from an EDA document or an IMF or gov.uk publication; everything else is marked.

If you also make devices

Egypt is the only market on this site that names the UK for both. The device page covers the separate instrument for devices marketed in Great Britain, requiring ISO 13485 plus UKCA certificates — a genuinely unusual position that no other regulator here matches. Two product types, one regulator, and Britain named in each.

The medical devices page for Egypt → · What an MHRA approval is worth in all six markets →